Tag Archive for: AMPLIVANT

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

/in

First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally. Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and […]

Read more

ISA Pharmaceuticals announces the start of clinical trial using its novel AMPLIVANT® technology

/in

AMPLIVANT® adjuvant technology has the potential to increase vaccine immune response 10 – 100 fold Modi-1 clinical trial to begin in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer Oegstgeest, The Netherlands, 14 April 2022 – ISA Pharmaceuticals today announces that a clinical trial using ISA’s novel AMPLIVANT® adjuvant […]

Read more